Boghdady W, Lotfy M, William E
El-Sahel Teaching Hospital.
Egypt Dent J. 1993 Jul;39(3):461-6.
The analgesic efficacy and tolerability of diclofenac-potassium 50 mg were compared with those of glafenine 200 mg in 109 outpatients suffering from moderate to severe dental pain. Throughout the four-day trial period, patients (Diclofenac-potassium: n = 58, mean age = 32.84 +/- 12.0 yrs. Glafenine n = 51, mean age = 34.12 +/- 14.0 yrs.) were randomised, in a double-blind fashion, to receive one tablet of either medications three times daily, together with an antibiotic, ampicillin, 500 mg, 8 hourly. Half an hour following the administration of the first analgesic dose, both treatment groups showed highly statistically significant (P < 0.001) reductions in the mean pain level when compared with their baseline values. The mean decrease of pain level in diclofenac-potassium group after 1/2 hour was significantly (P < 0.01) greater than that in the glafenine group. Moreover, the percent of pain free patients after 1/2 hour in the diclofenac-potassium group was significantly higher (P = 0.05) compared with those in the glafenine group. The mean decreases in pain and tenderness on the second and fourth days, in relation to their initial values, were greater in the diclofenac-potassium treated patients than the glafenine treated ones. The overall evaluation of therapeutic effect was considered excellent in 72% of the diclofenac- potassium patients compared with 57% of the glafenine patients. Furthermore, 95% of the diclofenac-potassium patients, compared with 90% of the glafenine ones, expressed their willingness to use the trial medication again in similar conditions. None of the patients in both treatment groups discontinued the trial due to unwanted effects. Both therapies were well tolerated. Only one patient (1.72%) in the diclofenac-potassium treatment group experienced slight diarrhoea. It can be concluded from this study that both medications are effective and well tolerated in the management of dental pain. However, diclofenac-potassium with its fast onset of effect is particularly suitable in the management of acute painful conditions.
将50毫克双氯芬酸钾的镇痛效果和耐受性与200毫克格拉非宁在109名患有中度至重度牙痛的门诊患者中的效果和耐受性进行了比较。在为期四天的试验期内，患者（双氯芬酸钾组：n = 58，平均年龄 = 32.84 ± 12.0岁。格拉非宁组：n = 51，平均年龄 = 34.12 ± 14.0岁）以双盲方式随机分组，每天三次服用其中一种药物的一片，同时服用抗生素氨苄西林500毫克，每8小时一次。在首次服用镇痛剂剂量半小时后，与基线值相比，两个治疗组的平均疼痛水平均有高度统计学意义的降低（P < 0.001）。双氯芬酸钾组半小时后疼痛水平的平均降低幅度显著大于格拉非宁组（P < 0.01）。此外，双氯芬酸钾组半小时后无痛患者的百分比显著高于格拉非宁组（P = 0.05）。与格拉非宁治疗的患者相比，双氯芬酸钾治疗的患者在第二天和第四天疼痛和压痛相对于初始值的平均降低幅度更大。双氯芬酸钾组72%的患者对治疗效果的总体评价为优秀，而格拉非宁组为57%。此外，95%的双氯芬酸钾组患者表示愿意在类似情况下再次使用试验药物，而格拉非宁组为90%。两个治疗组中均没有患者因不良反应而中断试验。两种疗法耐受性良好。双氯芬酸钾治疗组中只有一名患者（1.72%）出现轻微腹泻。从这项研究可以得出结论，两种药物在治疗牙痛方面均有效且耐受性良好。然而，起效迅速的双氯芬酸钾特别适用于治疗急性疼痛状况。
